Topical administration of Oftaquix® and Tobrex® in refractive surgery

Cover Page


Cite item

Abstract

Background: Due to the growing resistance of causative microorganisms to previous generations of antibiotics and to the risk of post-op infectious complications associated with it, an efficacy and safety assessment of modern fluoroquinolones’ prophylactic topical administration appears to be reasonable. Purpose: To investigate the efficacy and safety of levofloxacin 0.5 % ophthalmic solution (Oftaquix®, Santen, Finland) topical use in modern excimer laser refractive surgery (LASIK). Material and methods: Patients were randomized into two treatment groups: Thirty two patients (64 eyes) were treated with levofloxacin 0.5 % ophthalmic solution (Oftaquix®, Santen, Finland) b.i.d. and thirty patients (60 eyes) received tobramycine 0.3 % eye drops (Tobrex®, Alcon-Couvreur, Belgium) q. t.d., both during first 7 days post-op. LASIK procedure using excimer laser MEL-80 (Carl Zeiss Meditec, Germany) and mechanical microkeratome LSK Moria Evolution-2 (Moria, France) was performed in all patients for myopia from –1.0 to –12.0 D. Patient’s age varied from 18 to 40 years (mean age 28.4±7.8). Results: During topical application of Oftaquix® and Tobrex® in our refractive surgery patients there were no topical, or systemic adverse reactions, or allergic reactions. Oftaquix® and Tobrex® had good topical tolerability. Therapeutic dosage regimen, sufficient in terms of anti-infective prophylaxis, in case of Oftaquix® was twice as low in comparison to Tobrex®. Tear film break-up time (TFBUT) preand post-op was comparable between groups. In both groups, TFBUT post-op was significantly lower compared to pre-op values (p < 0.01). Tear production (Shirmer-I test) in both groups remained almost the same (p > 0.05). Conclusion: Oftaquix® (Santen, Finland) ophthalmic solution is effective and safe for prevention of infectious complications after LASIK and appears to be a rational alternative to tobramycine 0.3 % eye drops (Tobrex®, Alcon-Couvreur, Belgium).

About the authors

Andrey Borisovich Kachanov

S.N. Fyodorov Microsurgery Complex

Email: andrey_kachanov@yahoo.com
ophthalmologist, Candidate of Medical Science

Yulia Alexandrovna Pavlova

S.N. Fyodorov Microsurgery Complex

MD, ophthalmologist

Alexander Vladimirovich Vokhmyakov

Santen Oy Representation in Moscow

MD, ophthalmologist, scientific adviser

References

  1. Балашевич Л. И., Качанов А. Б. Клиническая корнеотопография и аберрометрия. — М.: 2008. — 167 с., ил.
  2. Саркисян К. А., Вохмяков А. В. Профилактика инфекционных и воспалительных осложнений после ЛАЗИК // Офтальмологические ведомости. — 2009. — Т. 2, № 3. — С. 17–22.
  3. Юсеф Ю. Н., Школяренко Н. Ю., Аладинская И. В. и др. Офтаквикс при факоэмульсификации катаракты//Вестник офтальмологии. — 2012. — Т. 128, № 6. — С. 54–56.
  4. Izdebska J., Szaflik J. P. Levofloxacin (oftaquix) a fluoroquinolone of a new generation in prevention of the postoperative endophthalmitis following uncomplicated cataract surgery — the study of the European Society of Cataract and Refractive Surgeons (ESCRS) // Klin. Oczna. — 2005. — Vol. 107, № 4–6. — P. 344–347.
  5. Keating G. M. Levofloxacin 0.5 % ophthalmic solution: a review of its use in the treatment of external ocular infections and in intraocular surgery // Drugs. — 2009. — Vol. 18; (69) № 9. — P. 1267–1286.

Copyright (c) 2013 Kachanov A.B., Pavlova Y.A., Vokhmyakov A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-65574 от 04 мая 2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies